VIGADRONE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VIGADRONE (VIGADRONE).
Irreversible inhibitor of GABA transaminase (GABA-T), leading to increased brain concentrations of gamma-aminobutyric acid (GABA).
| Metabolism | Minimal hepatic metabolism; primarily excreted unchanged in urine. |
| Excretion | Renal: 70% unchanged; hepatic metabolism: 20% (primarily via CYP4A7, not CYP450); fecal: <5%. |
| Half-life | Terminal elimination half-life: 5-7 hours in young adults; 12-15 hours in elderly; therapeutic steady-state achieved within 2-3 days. |
| Protein binding | Protein binding: <20%; primarily binds to albumin; low binding minimizes drug interactions. |
| Volume of Distribution | Volume of distribution: 0.8 L/kg; indicates extensive tissue distribution, particularly in brain and cerebrospinal fluid. |
| Bioavailability | Oral bioavailability: >80% for tablets; near 100% for oral solution due to rapid absorption. |
| Onset of Action | Oral: 1-2 hours for peak plasma concentration; clinical anticonvulsant effect occurs within 1-2 weeks due to adaptive mechanisms. |
| Duration of Action | Duration: 6-8 hours per dose based on half-life; clinical effect persists 24 hours due to sustained GABA-T inhibition, requiring once or twice daily dosing. |
Adults: 500 mg orally twice daily, may increase by 500 mg/day every week; maximum 1500 mg twice daily.
| Dosage form | FOR SOLUTION |
| Renal impairment | GFR 30-50 mL/min: 500 mg twice daily; GFR <30 mL/min: 250 mg once or twice daily; ESRD on dialysis: not recommended. |
| Liver impairment | No specific Child-Pugh based dose adjustments; use with caution in severe hepatic impairment. |
| Pediatric use | Infants (1 month to 2 years): 25-50 mg/kg/day divided twice daily; Children (2-16 years): 25-50 mg/kg/day divided twice daily; maximum 3 g/day. |
| Geriatric use | Initiate at lower dose (e.g., 250 mg twice daily) due to age-related renal decline; titrate slowly; monitor renal function. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for VIGADRONE (VIGADRONE).
| Breastfeeding | Vigabatrin is excreted into human breast milk with an estimated infant dose of 3-6% of maternal weight-adjusted dose. M/P ratio not established. Due to potential adverse effects on neurodevelopment, breastfeeding is not recommended during vigabatrin therapy. |
| Teratogenic Risk | First trimester: Major congenital malformations, including neural tube defects, cleft palate, and cardiac anomalies, with a dose-dependent risk. Second/third trimester: Fetal growth restriction, neurodevelopmental delay, and neonatal withdrawal symptoms. Risk is highest with polytherapy and doses >1000 mg/day. |
■ FDA Black Box Warning
Permanent bilateral concentric visual field constriction and other vision loss; risk increases with cumulative dose and duration. Not recommended unless benefit outweighs risk.
| Serious Effects |
Hypersensitivity to vigabatrin or any component of the formulation; concomitant use with other GABAergic drugs (relative) due to increased CNS depression.
| Precautions | Vision loss (monitor ophthalmologic exams at baseline and every 3 months), MRI signal abnormalities (T2 hyperintensities in basal ganglia/thalamus), suicidal ideation, withdrawal seizures (taper dose), somnolence/fatigue. |
Loading safety data…
| Fetal Monitoring | Baseline and serial fetal ultrasounds for anomaly detection; regular monitoring of maternal liver function, complete blood count, and visual fields (due to risk of visual field defects). Neonatal monitoring for sedation, poor feeding, and withdrawal symptoms after delivery. |
| Fertility Effects | No significant adverse effects on fertility have been reported in animal studies; human data limited. Hormonal contraceptive efficacy may be reduced due to CYP450 enzyme induction, requiring non-hormonal backup methods. |